Ironwood Pharmaceuticals (IRWD) Earns “Hold” Rating from Morgan Stanley

Ironwood Pharmaceuticals (NASDAQ:IRWD)‘s stock had its “hold” rating reaffirmed by investment analysts at Morgan Stanley in a report issued on Monday.

Several other research firms have also recently commented on IRWD. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. Credit Suisse Group assumed coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, November 27th. They issued a “buy” rating and a $19.00 target price for the company. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Mizuho restated a “buy” rating and issued a $20.00 target price (down previously from $23.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, August 25th. Finally, Cowen set a $20.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 21st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company’s stock. Ironwood Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $18.38.

Ironwood Pharmaceuticals (IRWD) traded up $0.05 during mid-day trading on Monday, hitting $17.32. 1,098,200 shares of the stock traded hands, compared to its average volume of 1,298,450. Ironwood Pharmaceuticals has a one year low of $13.43 and a one year high of $19.94. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The company had revenue of $86.80 million during the quarter, compared to analysts’ expectations of $73.59 million. During the same quarter last year, the business earned ($0.18) EPS. The business’s revenue was up 31.3% on a year-over-year basis. research analysts expect that Ironwood Pharmaceuticals will post -1.12 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. lifted its stake in shares of Ironwood Pharmaceuticals by 5.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 648 shares during the period. Aperio Group LLC lifted its stake in shares of Ironwood Pharmaceuticals by 11.9% in the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 1,410 shares during the period. Amalgamated Bank lifted its stake in shares of Ironwood Pharmaceuticals by 9.0% in the second quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 1,421 shares during the period. Virtu KCG Holdings LLC lifted its stake in shares of Ironwood Pharmaceuticals by 10.3% in the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,470 shares during the period. Finally, Legal & General Group Plc lifted its stake in shares of Ironwood Pharmaceuticals by 5.0% in the second quarter. Legal & General Group Plc now owns 47,773 shares of the biotechnology company’s stock valued at $900,000 after purchasing an additional 2,265 shares during the period.

WARNING: “Ironwood Pharmaceuticals (IRWD) Earns “Hold” Rating from Morgan Stanley” was first published by Week Herald and is the property of of Week Herald. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://weekherald.com/2017/12/04/ironwood-pharmaceuticals-irwd-earns-hold-rating-from-morgan-stanley.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply